# Iktos

Source: https://onco.cc/companies/iktos/  
OnCo record `iktos` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Iktos sells artificial intelligence software that designs new drug molecules and plans how to make them, and runs robotic labs that build and test the molecules automatically.

## Summary

Iktos, founded in 2016 and based in Paris, provides AI and robotics for small-molecule discovery. Makya is a generative AI software-as-a-service platform for de novo, multi-parameter optimised molecule design; Spaya is an AI retrosynthesis tool that maps target compounds back to commercially available starting materials; and Iktos Robotics operates autonomous synthesis, purification, analysis and imaging-based screening. The company reports more than 60 collaborations with pharmaceutical, biotech and academic partners including Pfizer, Takeda and Johnson and Johnson, and has three in-house programmes: MTHFD2 (inflammation and autoimmunity, with a 2026 patent publication), amylin receptor (obesity) and SKP2-CKS1 (immuno-oncology). In 2026 it launched Iktos Engine APIs for agentic workflows and was selected for a JETRO programme in Japan. The website mentions an EIC Accelerator grant but no round amounts or investors were on fetched pages.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Paris
- Type: ai-software
- Website: https://iktos.ai

## Notes

- Series A (reported elsewhere as EUR 15.5 million) and EIC grant amount not sourced, so no round recorded.

## Sources

- Official website: https://iktos.ai
- News and press: https://www.iktos.ai/resources/articles

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/)

---
JSON: https://onco.cc/api/v1/entities/iktos.json